CYP2D6*10和CYP2C19*2基因型多态性与接受他莫昔芬治疗乳腺癌患者生存率的相关性研究

目的: 研究CYP2D6^*10和CYP2C19^*2基因型多态性与接受他莫昔芬(tamoxifen, TAM)治疗乳腺癌患者生存率的相关性研究。方法: 选择2009至2004年本院甲乳外科和肿瘤内科收治的171名术后服用TAM治疗的雌激素阳性乳腺癌患者,调查TAM使用情况和生存状态等相关资料;收集相关的石蜡组织切片用于DNA提取;用PCR技术检测CYP2D6^*10和CYP2C19^*2基因型多态性;查明CYP2D6^*10和CYP2C19^*2基因型多态性与患者生存率的相关性。结果: 本次研究中,CYP2D6Wt/Wt、CYP2D6Wt/^*10和CYP2D6^*10/^*10基因型的总生存率(overall survival,OS)类似,差异无统计学意义(P>0.05)。CYP2C19^*2/^*2基因型的5年OS明显优于CYP2C19 Wt/Wt,差异具有统计学意义(P<0.05);CYP2C19^*2/^*2基因型的10年OS明显优于CYP2C19 Wt/Wt和CYP2C19 Wt/^*2,差异具有统计学意义(P<0.05);但是CYP2C19Wt/Wt与CYP2C19 Wt/^*2的5、10年OS差异无统计学意义(P>0.05)。结论: 研究结果显示,CYP2D6^*10基因型多态性与服用TAM治疗乳腺癌患者的生存率之间不存在相关性;CYP2C19^*2基因型多态性与接受TAM治疗乳腺癌患者的生存率之间存在相关性,CYP2C19^*2/^*2接受TAM治疗乳腺癌患者的生存率最高,CYP2C19 Wt/^*2生存率较高,CYP2C19 Wt/Wt较低。

Association between CYP2D6*10/CYP2C19*2 genotype polymorphism and survival of breast cancer patients receiving tamoxifen treatment

AIM: To observe the association between CYP2D6^*10 and CYP2C19^*2 genotype polymorphism and survival of breast cancer patient receiving tamoxifen (TAM) treatment.METHODS: 171 cases of breast cancer patient receiving TAM treatment were selected from breast surgery and medical oncology since 2004-2009. The service condition of TAM treatment and the survival state were examined, the paraffin section of patients were collected and used in DNA extract, the CYP2D6^*10 and CYP2C19^*2 genotype polymorphism were detected by PCR, and the association between CYP2D6^*10 and CYP2C19^*2 genotype polymorphism and survival of breast cancer patient receiving TAM treatment were ascertained.RESULTS: Overall survival (OS) of CYP2D6Wt/Wt, CYP2D6Wt/^*10 and CYP2D6^*10/^*10 were very similar (P>0.05). 5 years-OS of CYP2C19^*2/^*2 were significantly higher than that of CYP2C19 Wt/Wt group, and the difference was statistically significant (P<0.05); 10 years-OS of CYP2C19^*2/^*2 were significantly higher than that of CYP2C19 Wt/Wt or CYP2C19 Wt/^*2,and the difference was statistically significant (P<0.05); 5 or 10 years-OS of CYP2C19 Wt/Wt was similar to that of CYP2C19 Wt/^*2 (P>0.05).CONCLUSION: The CYP2D6^*10 genotype polymorphisms isn't associated with survival of breast cancer patient receiving TAM treatment. The CYP2C19^*2 genotype polymorphism is associated with survival of breast cancer patient receiving TAM treatment. The survival rate of breast cancer patient with CYP2C19^*2/^*2 receiving TAM treatment is the highest, that of CYP2C19 Wt/^*2 is medium, and that of CYP2C19 Wt/Wt is lower.